Drug Type Gene therapy |
Synonyms LGMD2B therapy(Atamyo Therapeutics) |
Target |
Mechanism DYSF gene stimulants(Dysferlin gene stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Atamyo Therapeutics SASStartup |
Active Organization Atamyo Therapeutics SASStartup |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Limb-Girdle Muscular Dystrophy, Type 2B | Preclinical | FR | Atamyo Therapeutics SASStartup | 09 Aug 2022 |